Understanding the migraine treatment landscape prior to the introduction of calcitonin gene‐related peptide inhibitors: Results from the Assessment of TolerabiliTy and Effectiveness in MigrAINe Patients using Preventive Treatment (ATTAIN) study

BACKGROUND: Calcitonin gene‐related peptide (CGRP) inhibitors were introduced in the United States (US) in 2018. To understand the changing patterns of preventive treatment following the introduction of these new agents, we must first characterize the patterns which preceded their introduction. OBJE...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Headache
Hauptverfasser: Kawata, Ariane K., Shah, Neel, Poon, Jiat‐Ling, Shaffer, Shannon, Sapra, Sandhya, Wilcox, Teresa K., Shah, Shweta, Tepper, Stewart J., Dodick, David W., Lipton, Richard B.
Format: Artigo
Sprache:Inglês
Veröffentlicht: John Wiley and Sons Inc. 2021
Schlagworte:
Research Submissions
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC8048891/
https://ncbi.nlm.nih.gov/pubmed/33594686
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/head.14053
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge